360° SearchNetwork Hot Spots Trends Time Series

INTUNIV

Type: Product

Name: INTUNIV

First reported May 17 2013 - Updated May 17 2013 - 1 reports

Shire To Present Scientific Data Across A Range Of Psychiatric Disorders At American Psychiatric Association Annual Meeting

PHILADELPHIAResearch explores data on treatments for psychiatric disorders; health economics and outcomes research also to be presented Shire plc (LSE: SHP, NASDAQ: SHPG), the global specialty biopharmaceutical company, announces that it will present ... [Published TheStreet.com - May 17 2013]

Entities: INTUNIV, VYVANSE, ADHD, Shire plc

First reported May 14 2013 - Updated May 14 2013 - 1 reports

TWi Pharmaceuticals Announces Tentative ANDA Approval for Guanfacine Hydrochloride Extended-Release Tablets

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact ... [Published KHNL News 8 - May 14 2013]

Entities: Guanfacine, TWi Pharmaceuticals, Taipei, INTUNIV, Taiwan

First reported May 10 2013 - Updated May 10 2013 - 1 reports

Actavis

FTSE 100 hits highest since October 2007

Central bank action, reasonable economic data and upbeat company results continued to support the market Leading shares rose for the seventh day in a row on Friday, with the FTSE 100 index closing above 6600 for the first time since October 2007.A combination ... [Published Guardian.co.uk - May 10 2013]

Entities: FTSE 100, 9p, Actavis, LIALDA

First reported May 08 2013 - Updated May 08 2013 - 1 reports

Watson Pharmaceuticals Inc

Shire settles pending litigations with Actavis and Watson

Shire LLC, a subsidiary of Shire plc, has settled all pending litigations with Actavis, Inc., an integrated pharmaceutical company, Actavis LLC, and Actavis Elizabeth LLC and Watson Laboratories, Inc.-Florida, Watson Pharma, Inc. and ANDA, Inc. in connection ... [Published Individual.com - May 08 2013]

Entities: Actavis, Watson Pharmaceuticals Inc, INTUNIV, Shire plc

First reported May 03 2013 - Updated May 03 2013 - 1 reports

Shire sets out strategy for growth in 2013

Shire has released its quarter one results and outlined its strategy for growth.The company has earned a ten per cent increase in non GAAP earnings, while growth has been delivered substantially higher than the mid-single digit industry levels.It also ... [Published Chromatography Today - May 03 2013]

Entities: Flemming Ornskov, FIRAZYR, VPRIV, LIALDA

First reported May 02 2013 - Updated May 03 2013 - 1 reports

Shire plc

Shire earnings jump but sales disappoint

Oliver HaillDrug maker Shire lifted first-quarter earnings 10 per cent but revenues missed consensus estimates by 5.0 per cent.Product sales in the three months to end-March 2013 were up 1.0% to $1.1bn against a strong set of comparatives from the equivalent ... [Published BullBearings - May 02 2013]

Entities: Shire plc, REPLAGAL, DERMAGRAFT

First reported May 02 2013 - Updated May 02 2013 - 1 reports

Chicago Bridge & Iron Company

The Zacks Analyst Blog Highlights: Chicago Bridge & Iron, Shire,..

The Zacks Analyst Blog Highlights: Chicago Bridge & Iron, Shire, Actavis, UCB and WuXi PharmaTechCHICAGO, May 2, 2013 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss ... [Published ADVFN Australia - May 02 2013]

Entities: Shire plc, Chicago Bridge & Iron Company, Actavis

First reported May 02 2013 - Updated May 02 2013 - 1 reports

Actavis First Quarter 2013 Net Revenue Increases 24% to $1.9 Billion

/PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today reported net revenue increased 24 percent to $1.90 billion for the first quarter 2013, compared to $1.52 billion in the first quarter 2012. On a non-GAAP basis, diluted earnings per share for the first quarter ... [Published NewsBlaze - May 02 2013]

Entities: Actavis, Crestor, Generic Version

First reported Apr 30 2013 - Updated Apr 30 2013 - 1 reports

Merger talks boost Actavis Investor's Business Daily

The generic-drug giant shares rose 4.6% to 105.58 after reports over the weekend of merger talks with Valeant Pharmaceuticals (VRX). The Wall Street Journal on Fri. reported a "merger of equals" worth at least $13 bil, but talks reportedly stalled on ... [Published Yahoo! Finance - Apr 30 2013]

Entities: Actavis, Mergers & Acquisitions, Valeant Pharmaceuticals International, INTUNIV

First reported Apr 27 2013 - Updated Apr 27 2013 - 1 reports

Actavis Settles OxyContin Patent Flap With Purdue; Seals Intuniv Deal With Shire

In a settlement agreement reached Friday, Purdue Pharma granted Actavis a license to sell a generic version of its abuse-deterrent OxyContin as early as January 1, 2 ... [Published FDA News - Apr 27 2013]

Entities: INTUNIV, OxyContin, Actavis

First reported Apr 25 2013 - Updated Apr 26 2013 - 12 reports

Actavis resolves Intuniv patent litigation with Shire

Actavis has resolved outstanding patent litigation concerning generic version of Intuniv (guanfacine hydrochloride), indicated for the treatment of attention deficit hyperactivity disorder, with Shire. ... [Published PBR - News - Apr 26 2013]

Entities: INTUNIV, Shire plc, Actavis, Patent Litigation

First reported Apr 25 2013 - Updated Apr 25 2013 - 4 reports

A Generic Version of Intuniv Will Be Launched In December 2014

Actavis, Inc., a leading specialty pharmaceutical company, today announced that is has reached a settlement agreement with Shire plc resolving outstanding patent litigation related to Actavis' generic version of INTUNIV@ (guanfacine hydrochloride) for ... [Published PharmaceuticalProcessing - Apr 25 2013]

Entities: INTUNIV, Actavis, Generic Version

Quotes

"Shire is committed to research in the field of neuroscience and developing treatment options for conditions that have significant unmet patient need, such as MDD and BED" said Arnaud Partiot, MD, PhD, Shire senior vice president, Research and Development

Shire To Present Scientific Data Across A Range Of Psychiatric Disorders At American Psychiatric ... [Published TheStreet.com - May 17 2013]

"We are pleased to receive the tentative approval from U S FDA for our Guanfacine Hydrochloride product" said Dr. Calvin C Chen

TWi Pharmaceuticals Announces Tentative ANDA Approval for Guanfacine Hydrochloride Extended-Relea ... [Published KHNL News 8 - May 14 2013]

Analyst Peter Verdult at Morgan Stanley said: "This news provides a much needed tonic, given the weak first quarter performance, and lack of significant pipeline data until 2014.Shire is committed to delivering revenue growth of more than 5% per annum, whilst moving to a flatter/more scalable operating structure involving five units (Rare Diseases, CNS, GI, Regenerative & Internal Medicine – ophthalmology) and a single R&D organisation. Efforts to bolster the mid/late stage pipeline are set to intensify."

FTSE 100 hits highest since October 2007 [Published Guardian.co.uk - May 10 2013]

...the first quarter, Shire made three acquisitions - Lotus Tissue Repair, Premacure and SARcode BioSciences, and Dr Ornskov noted that the last two "provide us with the foundation to build a potential new business unit in ophthalmology – a growing market" . A pipeline review is under way and already two studies have been stopped

New Shire chief sets out strategy as sales disappoint [Published Pharma Times - May 03 2013]

More Content

sort by: Date \| Relevance
Shire To Present Scientific Data Across A Range... [Published TheStreet.com - May 17 2013]
Shire to Present Scientific Data Across a Range... [Published PR Newswire - May 17 2013]
TWi Pharma receives tentative approval for Guan... [Published PharmaBiz - May 16 2013]
TWi Pharmaceuticals Announces Tentative ANDA Ap... [Published KHNL News 8 - May 14 2013]
TWi Pharmaceuticals Announces Tentative ANDA Ap... [Published PR Newswire - May 14 2013]
FTSE 100 hits highest since October 2007 [Published Guardian.co.uk - May 10 2013]
Shire settles pending litigations with Actavis ... [Published Individual.com - May 08 2013]
ADHD Drug Development is ‘Problematic,’ Drug Re... [Published Pharma-Mag - May 08 2013]
Shire sets out strategy for growth in 2013 [Published Chromatography Today - May 03 2013]
Shire Beats Earnings in 1Q - Analyst Blog [Published Quote.com United States - May 03 2013]
New Shire chief sets out strategy as sales disa... [Published Pharma Times - May 03 2013]
Shire earnings jump but sales disappoint [Published BullBearings - May 02 2013]
Shire PLC Earnings: Here’s Why Investors Don’t ... [Published Wall St. Cheat Sheet - May 02 2013]
The Zacks Analyst Blog Highlights: Chicago Brid... [Published ADVFN Australia - May 02 2013]
Shire PLC Earnings: Here’s Why Investors Don’t ... [Published Wall St. Cheat Sheet - May 02 2013]
The Zacks Analyst Blog Highlights: Chicago Brid... [Published FinanzNachrichten.de - May 02 2013]
Actavis Beats on Earnings, Raises View Zacks [Published Yahoo! Finance - May 02 2013]
The Zacks Analyst Blog Highlights: Chicago Brid... [Published Yahoo! Finance - May 02 2013]
Actavis First Quarter 2013 Net Revenue Increase... [Published NewsBlaze - May 02 2013]
Merger talks boost Actavis Investor's Business ... [Published Yahoo! Finance - Apr 30 2013]
Biopharma/ Diagnostic Stocks to Watch; (ASTX), ... [Published InvestorIdeas.com - Apr 29 2013]
Actavis Settles OxyContin Patent Flap With Pur... [Published FDA News - Apr 27 2013]
Actavis resolves Intuniv patent litigation with... [Published PBR - News - Apr 26 2013]
A Generic Version of Intuniv Will Be Launched I... [Published PharmaceuticalProcessing - Apr 25 2013]
Shire Settles Suit With Actavis to Delay Intuni... [Published BusinessWeek - Apr 25 2013]
Shire subsidiaries settled litigation with Acta... [Published Coutts Woman - Apr 25 2013]
Shire Settles All Pending Litigation With Actav... [Published TheStreet.com - Apr 25 2013]
Shire Settles All Pending Litigation with Actav... [Published NewsBlaze - Apr 25 2013]
Shire Settles All Pending Litigation with Actav... [Published Stockwatch - Apr 25 2013]
Shire Settles with Actavis and Watson over Gene... [Published FOXBusiness.com - Apr 25 2013]

Blogs

sort by: Date \| Relevance
ADHD Drug Development is ‘Problematic,’ Drug Re... [Published Pharma-Mag - May 08 2013] While high disease prevalence is encouraging pharmaceuticals companies to enter into the ADHD market, a lack of understanding surrounding the condition is making drug development problematic, states GBI Research in a new report focusing on the disease ...
Shire PLC Earnings: Here’s Why Investors Don’t ... [Published Wall St. Cheat Sheet - May 02 2013] Shire PLC ( NASDAQ:SHPG ) delivered a profit and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are down 3.26%.Markets are at 5-year ...
Shire PLC Earnings: Here’s Why Investors Don’t ... [Published Wall St. Cheat Sheet - May 02 2013] Shire PLC ( NASDAQ:SHPG ) delivered a profit and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are down 3.26%. Markets are at ...
Actavis resolves Intuniv patent litigation with... [Published PBR - News - Apr 26 2013] Actavis has resolved outstanding patent litigation concerning generic version of Intuniv (guanfacine hydrochloride), indicated for the treatment of attention deficit hyperactivity disorder, with Shire. ...
Analysts: Apple May Miss Guidance and 4 New Opi... [Published Wall St. Cheat Sheet - Mar 12 2013] Apple ( NASDAQ:AAPL ): Jefferies believes that there is a 25 percent chance that Apple will miss its Q1 guidance as a result of slowing sales during the second half of the quarter after the Samsung Galaxy S4 launch event this Thursday. Additionally, ...

Press Releases

sort by: Date \| Relevance
Shire to Present Scientific Data Across a Range... [Published PR Newswire - May 17 2013]
TWi Pharmaceuticals Announces Tentative ANDA Ap... [Published PR Newswire - May 14 2013]
Shire Settles All Pending Litigation with Actav... [Published PR Newswire: Health - Apr 25 2013]
Actavis Reaches Agreement with Shire to Launch ... [Published PR Newswire: Health - Apr 25 2013]